Find your next paid study

Baylor College of MedicineNCT06176690

Phase 2

A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and p…

Angioimmunoblastic T-cell LymphomaEnteropathy-Associated T-Cell LymphomaFollicular T-Cell Lymphoma+4 more

Alliance for Clinical Trials in OncologyNCT04803201

Phase 3

A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected si…

Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell LymphomaFollicular T-Cell Lymphoma+4 more

Corvus Pharmaceuticals, Inc.NCT06561048

~$10 – $8,750

Phase 3

A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients With Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)

This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with periphera…

Anaplastic Large Cell Lymphoma, ALK-NegativeFollicular Helper T-Cell LymphomaFollicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type+1 more

Eastern Cooperative Oncology GroupNCT06724237

~$10 – $7,500

LymphomaNon-Hodgkin LymphomaHodgkin Lymphoma+4 more

A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies

This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monot…

~$10 – $7,500

AstraZenecaNCT06137144

Relapsed and/or Refractory Mature T Cell MalignancyPeripheral T-Cell LymphomaAngioimmunoblastic T-cell Lymphoma+7 more

A Phase I Trial of Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

Background: Chemokine receptor 4 (CCR4) is a protein that is found on the surface of certain T-cell lymphoma cells and is common in mature T-cell cancers. Whi…

National Cancer Institute (NCI)NCT07055477

~$10 – $5,625

Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)

The SCORE-NHL study is a prospective, multi-center, study designed to collect data and biological samples from participants diagnosed with aggressive Stage I t…

Non-Hodgkin LymphomaT-Cell LymphomaDiffuse Large B-Cell Lymphoma+7 more

Follicular Helper T-Cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise Specified

~$10 – $1,050

Natera, Inc.NCT07750886

Phase 2

A Phase II Study of Duvelisib Maintenance After First-Line Therapy for Peripheral T-Cell Lymphoma

This phase II trial tests how well duvelisib works as treatment that is given to help keep cancer from coming back after it has disappeared following the initi…

City of Hope Medical CenterNCT07293403

Folliculotropic Mycosis FungoidesRecurrent Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Mycosis Fungoides+5 more

A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma

This randomized phase I/II trial studies the best dose and side effects of durvalumab and to see how well it works with or without lenalidomide in treating pat…

City of Hope Medical CenterNCT03011814

Diffuse Large B-Cell Lymphoma (DLBCL)Hodgkin LymphomaPeripheral T-cell Lymphoma (PTCL)+2 more

Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)

This Phase I study will evaluate the safety of autologous Epstein-Barr virus-specific T lymphocytes modified to express a constitutively active IL7 receptor (C…

The Methodist Hospital Research InstituteNCT07729397

Recurrent Anaplastic Large Cell LymphomaRecurrent Enteropathy-Associated T-Cell LymphomaRecurrent Follicular Helper T-Cell Lymphoma+23 more

Phase 1 Investigation of Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma

This phase I trial tests the safety, side effects and best dose of azacitidine in combination with belinostat and how well the combination works in treating pa…

Peripheral T Cell LymphomaRelapsed Peripheral T-Cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise Specified+4 more

MC1684 Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms

This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) …